

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV000521205US
DATE OF DEPOSIT 19 OCTOBER 2001

Attorney Docket No. P32293

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/01522	19 April 2000	23 April 1999

TITLE OF INVENTION
NOVEL PHARMACEUTICAL

APPLICANT(S) FOR DO/US

Paul David James BLACKLER, Robert Gordon GILES, Stephen MOORE and Michael John SASSE

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

In the Specification:

Kindly add the Abstract enclosed herewith on a separate sheet, at the end. ✓

In the Claims:

Please cancel claims 11-13. ✓

Please amend claims 1, 3-8, and 14 as follows: ✓

1. (Amended) A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) comprising:

- (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm^{-1} ; and/or
- (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm^{-1} ; and/or
- (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and/or
- (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

3. (Amended) A Polymorph according to claim 1, which provides a Raman spectrum substantially in accordance with Figure II.

4. (Amended) A Polymorph according to claim 1, which provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.